In 2023, an estimated 13.3 million Medicare beneficiaries enrolled in Parts A and B had obesity or overweight, based on having BMI of 27 or more recorded in claims or encounter data, or 24% of Medicare beneficiaries overall (Figure 1)
Brand Exenatide is not on the formulary but can be accessed through the NF exceptions pathway: criteria same as above + trial and failure with three preferred products (Ozempic, Rybelsus, Trulicity, Byetta, Bydureon, or Mounjaro)
Retatrutides triple receptor profile offers a unique opportunity to study interconnected pathways involved in appetite control, energy expenditure, lipid metabolism, and metabolic dysfunction
At the same time, GLP-1 RAs have shown promise in improving cognitive function, not only in diabetes but also in neurodegenerative diseases like PD and Alzheimers disease
Fedoruk RP, Lee CH, Banoei MM, Winston BW
The mental preoccupation with food that many people with obesity describe, sometimes called food noise, tends to fade